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Abstract
Background: To quantify the economic impact of sight loss and blindness in the United Kingdom (UK) population,
including direct and indirect costs, and its burden on health.
Methods: Prevalence data on sight loss and blindness by condition, Census demographic data, data on indirect
costs, and healthcare cost databases were used. Blindness was defined as best corrected visual acuity (BCVA) of
< 6/60, and sight loss as BCVA < 6/12 to 6/60, in the better-seeing eye.
Results: Sight loss and blindness from age-related macular degeneration (AMD), cataract, diabetic retinopathy,
glaucoma and under-corrected refractive error are estimated to affect 1.93 (1.58 to 2.31) million people in the UK.
Direct health care system costs were £3.0 billion, with inpatient and day care costs comprising £735 million (24.6%)
and outpatient costs comprising £771 million (25.8%). Indirect costs amounted to £5.65 (5.12 to 6.22) billion. The
value of the loss of healthy life associated with sight loss and blindness was estimated to be £19.5 (15.9 to 23.3)
billion or £7.2 (5.9 to 8.6) billion, depending on the set of disability weights used. For comparison with other
published results using 2004 disability weights and the 2008 estimates, the total economic cost of sight loss and
blindness was estimated to be £28.1 (24.0 to 32.5) billion in 2013. Using 2010 disability weights, the estimated
economic cost of sight loss and blindness was estimated to be £15.8 (13.5 to 18.3) billion in 2013.
Conclusions: The large prevalence of sight loss and blindness in the UK population imposes significant costs on
public funds, private expenditure, and health. Prevalence estimates relied on dated epidemiological studies and
may not capture recent advances in treatment, highlighting the need for population-based studies that track the
prevalence of sight-impairing eye conditions and treatment effects over time.
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Background
Sight loss and blindness cause a considerable amount of
health burden globally. In the UK, the burden due to sight
loss and blindness has increased from around 143,600 to
more than 154,600 disability adjusted life years, while the
total disability adjusted life years due to all causes in the
UK have been decreasing [1]. Demographic ageing is lead-
ing to a substantial increase in the prevalence of age-re-
lated sight-impairing conditions, and associated increases
in their costs [2]. However, a significant proportion of
sight loss and blindness is preventable, suggesting that
more investment in prevention and early intervention
could improve socioeconomic outcomes in the UK [3].
Estimating the cost of sight loss and blindness is
essential if their socioeconomic impact is to be fully
understood and if the cost effectiveness of prevention
and treatment is to be calculated. Calculation of the eco-
nomic cost in the UK is necessary as an input to assist
decision makers to evaluate policy and to prioritise
health expenditure, including research expenditure.
Moreover, it is necessary to understand how certain
costs are changing over time, and whether any progress
has been made against key objectives, including
eliminating preventable sight loss and blindness through
effective interventions such as screening and early inter-
vention with treatments.
To date, there has been little work estimating the eco-
nomic impact of sight loss and blindness specifically in
the UK context [2], although a study for the Royal
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National Institute of Blind People exists that estimates
the prevalence and cost of sight loss and blindness in
2008 [4]. Previous peer-reviewed studies have aimed to
identify the unit costs of sight loss and blindness for use
in cost-effectiveness analysis [5], with limited focus
placed on estimating the overall impact.
Internationally, a substantial body of literature exists
that estimates various costs associated with sight loss
and blindness, including direct medical costs, indirect
costs and intangible costs. A recent paper summarised
22 cost of illness and intervention studies, including one
study in the UK, finding that the mean annual expenses
per person for sight loss and blindness range from
US$12175 to US$24180 depending on severity [6]. How-
ever, very few cost of illness studies related to sight loss
or blindness have been published in peer-reviewed litera-
ture, and none have been published within the UK con-
text. In Canada, the socioeconomic impact of sight loss
and blindness was estimated to be £26,587 per person
with sight loss or blindness [7]. In Japan, the cost was
estimated to be £28,672 per person with sight loss or
blindness [8]. Both values were converted using purchas-
ing power parity in 2007.
This research has calculated the prevalence and cost
of sight loss and blindness specifically for the UK con-
text in 2013, to provide more current estimates of the
various cost components and to compare the changes
over the five years since the original Access Economics
study was conducted for the UK. This research enables
unique comparisons of the socioeconomic impact of
sight loss and blindness across countries by using a
methodology consistent with work previously conducted
in Canada, Australia, Japan and the US. Moreover, this re-
search provides useful analysis of the changing cost of
sight loss and blindness within the UK. As such, this re-
search will help inform decision-making with regards to
policy and commissioning of effective interventions for
prevention, detection, treatment and care of sight loss and
blindness and to provide direction for future research.
Methods
The costing methodology used in this study is based on
a prevalence approach to cost measurement [9]. Preva-
lence approaches measure the number of people with a
given condition in a base period and the costs associated
with treating them, as well as other financial and non-
financial costs in that year due to the condition. This ap-
proach is combined with both top-down and bottom-up
approaches to estimate expenditure for each condition.
[9]. To identify materials of relevance to this study, a lit-
erature review was conducted for each cost component,
noting this review was targeted rather than systematic
since the former was considered more fit-for-purpose
given this was a cost of illness study where many of the
inputs are in data sets and grey literature (e.g. govern-
ment documents) not in peer-reviewed literature.
Prevalence
To determine prevalence, sight loss and blindness for
this research are defined as:
 blindness (severe sight loss) is defined as best
corrected visual acuity (BCVA) of < 6/60 in the
better-seeing eye; and
 sight loss is defined as BCVA of < 6/12 to 6/60 in
the better-seeing eye.
A number of data sources, both local and inter-
national, were utilised to estimate the prevalence of sight
loss and blindness by age, gender, ethnicity, severity and
major cause (Additional file 1). Prevalence rates were ad-
justed for comorbidity using relativities of each condi-
tion to total sight loss and blindness. Total sight loss
and blindness data by cause were derived by five year
age groups. Within age groups, the relativities between
the visual acuity groupings were used to separate total
prevalence. For example, for those aged 75 and above
the Medical Research Council (MRC) trial of assessment
and management of older people in the community was
used to establish overall prevalence [10], including the
relativities between BCVA < 6/18, 6/18–6/30, and < 6/60
– the visual acuity groupings reported in the study. [11]
The relativities of each condition were then applied to
the total prevalence to adjust for comorbidities [11–14].
The prevalence rates for the other age groups were de-
rived in a similar way. Ethnicity splits [15–22], calculated
based on relative risks for specific eye disease type, were
applied to the prevalence rates by age. Where these were
not available, prevalence rates were assumed to be
the same as for the general population (i.e. no
difference by ethnicity group). Detailed tables and
methodology outlining the prevalence rate estimates
by age, gender and condition are available in the sup-
plementary file (Additional file 1).
These derived prevalence rates were applied to popula-
tion estimates by age, gender, ethnicity and region from
the 2011 UK Census and sub-national population pro-
jections for government office regions developed by the
Office for National Statistics (ONS). [23, 24] Greater
London Authority projections of the London population
by ethnicity, gender and five-year age group between
2013 and 2041 were utilised to project ethnicity groups
to 2051 across the entire UK population as they were
the only publicly available projections that provided age
and gender breakdowns for ethnic groups [25]. Average
annual growth rates between 2013 and 2041, calculated
for each ethnicity group and by five-year age groups,
were assumed to apply for the period between 2041 and
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2051. The total projected population, by each age and
gender group were adjusted to coincide with ONS popu-
lation projections [26], with each ethnicity group main-
taining the same relative share of the total population.
Health care system expenditure- direct costs
Direct health system costs were determined using a
combination of a top down and bottom up approach. [9]
The top down approach is based on Reference Cost data
collected by the Department of Health in England [27].
Health care services within the Reference Cost data are
broken down into Healthcare Resource Groups
(HRGV.4+) and contain 58 HRG codes that specifically
related to eye disease. To determine hospital inpatient
expenditure, each HRG code was mapped to each condi-
tion. Alternative sources such as Scotland’s Health Ser-
vice Costs [28], Wales’ Health Statistics Wales [29], and
Northern Ireland’s Reference Costs [30] were used for
other devolved nations. Non-admitted expenditure was
also estimated using these data. Non-admitted expend-
iture consists of outpatient costs and other community
services, including paramedic services, consultant led
outpatient attendances and non-consultant led out-
patient attendances.
Other health system expenditure was constructed
using a ‘bottom up’ approach [9]. This includes costs as-
sociated with sight loss and blindness from prescribing
expenditure, general ophthalmic services, injurious falls,
research and development (R&D), residential and com-
munity care, and capital and administration.
Expenditure data associated with prescriptions such as
ranibizumab (Lucentis), aflibercept (Eylea), anti-infective
eye preparations, corticosteroids, mydriatics, cyclople-
gics, local anaesthetics and other ophthalmic prepara-
tions was sourced from each devolved nation’s statistical
reports as appropriate using national formulary classifi-
cations to ensure the prescription is related to sight loss
or blindness [31–34]. For example, in England this is the
British National Formulary [31].
Similarly, data on general ophthalmic services [35–38],
residential and community care attributable to sight loss
or blindness [28, 39–41], and capital and administration
attributable to sight loss or blindness [29, 42–44] were
also sourced from each devolved nation’s statistical re-
ports as appropriate. Residential and community care
data sources indicate the number of recipients with sight
loss or blindness. To estimate the total cost of residential
and community care services, average unit costs for resi-
dential and community care – derived by dividing total
expenditure by total services – were applied to each resi-
dential and community care service. To attribute capital
and administration costs to sight loss and blindness, it
was assumed that total capital and administration ex-
penses are incurred at the same rate as the overall health
expenditure in England, of which 2.0% is for sight loss
and blindness [45].
The government sources outlined do not provide suffi-
cient information to estimate the private health care ex-
penditure associate with sight loss. As the public versus
private health care expenditure split for health services
has been relatively stable over the past two decades
with public spending only rising 3% of the total ex-
penditure by 2015 [46], private health care expend-
iture was derived using data from Williams et al.
(2000) [47]. Expenditure associated with injurious falls
due to sight loss and blindness was derived using
hospital episode statistics [48] and a model developed
by Scuffham et al. (2002) [49].
R&D expenditure attributable to sight loss and blind-
ness was estimated by applying the share of eye and ear
health R&D [50] to total health related R&D investment
from private industry, non-profit organisations and pub-
lic funds through the government [51]. To separate eye
and ear health R&D, expenditure for eye related R&D
was assumed to maintain the same proportion as the es-
timated disease burden attributable to ear and eye health
from the World Health Organization (WHO) Global
Burden of Disease project for high income countries
[52]. This measure was also validated against the most
recent Global Burden of Disease project for the UK,
which showed that the measure was not sensitive to
changes over time with the measure being 29.1% using
the more recent approach rather than 29.8% using the
earlier approach for high income countries [1, 52].
Indirect costs:
There are two types of indirect costs of sight loss and
blindness: the financial costs associated with lower
productivity from premature mortality, lower work-
force participation and absenteeism, and the cost of
informal carers, aids and modifications and
deadweight losses; and the non-financial costs from
loss of healthy life, that are analysed in terms of
disability adjusted life years (DALYs).
In evaluating indirect costs, it is important to make
the economic distinction between real costs and
transfer payments. Rather than payments made for
the use of any good or service, transfer payments are
a transfer of claims over real resources. Transfer costs
are important to estimate in order to attribute who
bears the costs of sight loss and blindness, and to cal-
culate the deadweight loss to society.
A human capital approach is adopted to estimate
productivity losses [9, 53]. Employment rates are lower
for people with sight loss relative to the average person
in the UK (after age standardisation) [54]. It is assumed
that, in the absence of sight loss, people with sight loss
would participate in the labour force and obtain
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employment at the same rate as other people in the UK
and earn the same average weekly earnings.
To estimate premature mortality rates from sight loss
and blindness in 2013, the country specific mortality rate
[55–57] was multiplied by an odds ratio of 2.34, which
was derived from the Melbourne Visual Impairment
Project (MVIP) [58]. Deaths due to sight loss and blind-
ness by age and gender were calculated from the demo-
graphic data and mortality rates utilising the attributable
fraction approach.
The productivity loss from those who die prema-
turely was estimated based on the assumption that if
they had lived, the person would have earned an aver-
age annual income up until their retirement. Average
gross annual incomes were calculated as £29,297 for
males and £23,946 for females in England, £26,702
for males and £21,939 for females in Wales, £28,304
for males and £23,608 for females in Scotland, and
£24,825 for males and £22,958 for females in North-
ern Ireland [59]. No on-costs have been included in
calculating productivity losses.
Retirement age was represented by the State Pension
age. The eligibility age for the State Pension is increasing
in the UK over the next decade. For the purposes of esti-
mating the productivity loss associated with premature
mortality, this was set at the 2013 eligibility age, which
was 65 for males and 62 for females. Average life expect-
ancy was assumed to be 79 for males and 83 years for fe-
males. For the age brackets 75–84 and 85+ for both
males and females, life expectancy was assumed to be
85 years and 90 years respectively [60].
The number of people who were in employment at the
time of their death was calculated by multiplying the
number of deaths due to sight loss or blindness by the
employment rate of those with ‘difficulty seeing’, which
on average was 55.5% [54]. The present value of lost
earnings (gross) was calculated using a discount rate of
3.5% over the number of years until retirement with sen-
sitivity analysis at 1.5%, as recommended by the National
Institute for Health and Care Excellence [61].
In addition to workforce separation, people with sight
loss or blindness may be absent from work more often
due to their condition. Access Economics (2006) [62] es-
timated that people with sight loss or blindness in the
United States were likely to have an additional 4.1 days
off work per year on average [7, 8]. Productivity costs
from increased absenteeism were calculated as the aver-
age number of days absent per year due to sight loss or
blindness adjusted for employment [7, 8].
Total informal care costs were calculated based on a
top-down approach using the 2011 Census data to deter-
mine the number of informal care hours provided to
people with sight loss, adjusted for population growth to
2013. An opportunity cost methodology [62–64] was
used to value these hours, which measures the value in
alternative use of time spent caring. This is valued by
productivity losses (or value of leisure time) associated
with caring.
The total number of hours of informal care were
calculated with the same methodology used by the
University of Leeds in valuing informal carers for
Carers UK [65]. The cost of informal care related to
sight loss and blindness was estimated as the total
number of informal care hours multiplied by the
average per hour wage rate for males and females, de-
rived from the average annual incomes [59].
The total annual cost of devices and modifications was
derived from data from a study conducted by Lafuma et
al. (2006) [66] in 2004. Prices were converted into Ster-
ling by applying the exchange rate used within their
study (£1 = €1.5) and adjusted to 2013 prices using an
average UK inflation rate over that period of 2.71% [67].
Real costs use up resources, or reduce the econo-
my’s overall capacity to produce goods and services.
In contrast, transfer payments involve payments from
one economic agent to another and include taxation
revenue or social welfare payments, which impose
deadweight losses on society. Deadweight losses asso-
ciated with sight loss and blindness include the cost
of raising additional revenue to fund public health
care system costs, residential and community care,
aids and equipment, and direct payments to those
with sight loss and blindness and their carers.
While the costs associated with deadweight loss de-
pend on the method used to raise additional taxes, the
social cost is not zero and has therefore been included
as a cost of sight loss and blindness. This study assumes
that additional taxes are raised through income tax rate
changes. The average marginal cost of raising additional
tax revenue was calculated as 1.12 [68], so for every add-
itional £1 raised by the UK government to fund costs as-
sociated with sight loss and blindness, there is an
estimated £0.12 of deadweight loss. Direct payments
from the government to those with sight loss were
sourced from the Department for Work and Pensions
[69] and the Department of Social Development [70] for
Northern Ireland.
Burden of disease
The overall impact on wellbeing from disability and pre-
mature death can be measured as “burden of disease”,
measured in DALYs. DALYs have two components – the
years of healthy life lost due to disability (YLD) and the
years of life lost due to premature death (YLL).
The method to quantify the reduction in the stock of
health capital is the global burden of disease method-
ology developed by the WHO [71].
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In any year, the disability weight of a disease (for ex-
ample, 0.43 for blindness) reflects a relative health state.
This example represents losing 43% of a year of healthy
life because of blindness. The loss of wellbeing for sight
loss was estimated using disability weights as per the
global burden of disease study from 2004 and 2010,
noting the existing debates surrounding the method-
ologies used to generate each set of disability weights
[72–76]. Both sets of disability weights are validated
measures and undergo considerable peer review at
the time of publication. Presenting the loss of well-
being using both sets of disability weights has added
benefits of enabling comparison with not only the
earlier Access Economics study, but also new studies
going forward that are based on the 2010 disability
weights. Each set of disability weights was applied to
prevalence data to calculate DALYs.
The method to value a reduction in the stock of health
capital has been based on Mason et al. (2008) [77] using
estimates of the value of a statistical life (VSL) derived
from the UK Department of Transport. The UK Depart-
ment of Transport estimated the VSL to be £1.43 million
in 2005 prices. Mason et al. estimated, the value of a year
of perfect health to be £70,896 (in 2005 prices), by apply-
ing a discount rate of 1.5%. This is the rate of pure time
preference and differs from the standard 3.5% discount
rate as the VSL has been shown to grow at a similar rate
as the marginal utility of consumption (approximately
2%), and should therefore be excluded [77]. This estimate
for the value of a DALY was adjusted to 2013 prices using
UK consumer price index to give £88,825.
Results
Prevalence
In 2013, there were an estimated 1.93 (1.58 to 2.31) mil-
lion people with sight loss and blindness in the UK as a
whole, or 3.0% (2.5% to 3.6%) of the population. This in-
cludes 255,000 (208,100 to 304,800), or 13.2% who are
blind. The ethnic groups with highest prevalence were
white people (3.3%, range 2.7% to 3.9%), followed by
Asians (1.5%, range 1.2% to 1.8%). The prevalence of
sight loss and blindness in the UK was estimated to have
increased by 135,115 (7.5%) since 2008.
The prevalence of sight loss and blindness is pro-
jected to increase with demographic ageing, and in a
policy neutral environment, from 3.0% (2.5% to 3.6%)
today to 5.4% (4.4% to 6.5%) or approximately 4 mil-
lion people by 2050. In terms of ethnic shares relative
to the total population with sight loss and blindness,
the share of white people with sight loss and blind-
ness is projected to fall (from 94.9% to 88.5%), while
the share of black people is projected to increase
from 1.0% to 1.8%, Asians from 3.0% to 6.4%, and
other ethnicities from 1.1% to 3.3%.
From 2013 to 2050, the share of sight loss and blind-
ness from AMD is projected to change from 23.1% to
29.7%, more than doubling from 445,809 (363,900 to
532,800) people to 1.23 (1.01 to 1.47) million people.
The share contributed from cataract is projected to
change from 18.7% to 21.4%, diabetic retinopathy from
4.7% to 3.1%, glaucoma from 7.2% to 7.0%, under-
corrected refractive error from 38.9% to 31.3% while
other eye diseases remains constant in its share of total
prevalence (rising in absolute terms only).
Health system costs- direct costs
Direct health care system costs are estimated to amount
to £2.99 billion in UK in 2013. Around 50% of total dir-
ect health care system costs are attributable to hospital
recurrent expenditure and non-admitted expenditure,
totalling around £1.5 billion. Further significant cost
items include general ophthalmic services (£614.6 mil-
lion or 21%), prescribing expenditure (£380.9 million or
13%), and residential and community care services
(£276.8 million or 9%). Other costs include costs due to
injurious falls, an attributable portion of capital and ad-
ministration costs and research and development relat-
ing to sight loss and blindness (Table 1).
AMD accounted for 34% of total health system costs
that could be attributed to each of the five conditions
(this total excludes residential care and community care
services, expenditure associated with injurious falls and
capital and administration expenditure). This repre-
sents the rapid growth in costs associated with the
new anti-vascular endothelial growth factor (VEGF)
therapies such as ranibizumab (Lucentis) and Afliber-
cept (Eylea). Under-corrected refractive error, cataract,
diabetic retinopathy, glaucoma and other eye diseases
accounted for 21%, 20%, 10%, 7% and 8% of total
health system costs, respectively.
Indirect costs
The total of indirect costs attributable to sight loss and
blindness in the UK were estimated to be £5654 (5117
to 6224) million in 2013. Indirect costs for each country
are shown in Table 2.
Lower employment participation for those with sight
loss and blindness resulted in 90,108 (73,500 to 107,700)
fewer people in the UK workforce in 2013 and an esti-
mated loss of £2.43 (1.98 to 2.90) billion in income (44%
of indirect costs).
The second largest indirect cost component is attribut-
able to informal care, estimated to be around £2.36 bil-
lion (or 43%) in 2013. Other indirect costs associated
with sight loss and blindness in 2013 include expend-
iture on devices and modifications (£409.6 million or
7%, range 334.3 to 489.6 million), deadweight loss
(£379.0 million or 7%, range 378.5 to 379.4 million),
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absenteeism and premature mortality (together, 1% of
indirect costs). In the working age population, an esti-
mated 25 (20 to 30) deaths were attributable to sight loss
and blindness in 2013, of which 14 (11 to 17) would
have been employed.
Burden of disease
Using disability weights from the 2004 global burden of
disease project for comparison with the 2008 estimates
and older international studies, the YLDs lost due to
sight loss and blindness were estimated as 205,372
(167,600 to 245,500) DALYs in the UK in 2013. Based
on the number and age-gender profile of deaths, the
YLLs from sight loss and blindness were estimated to be
13,734 (11,200 to 16,400), bringing the total to 219,106
(178,800 to 261,900) DALYs. The proportion of DALYs
attributable to each condition are shown in Fig. 1.
Total DALYs were multiplied by £88,825 (the value
of a DALY) to provide an estimate of £19.5 (15.9 to
23.3) billion for the total cost associated with the loss
of wellbeing. The cost was estimated to be £16.3
(13.3 to 19.5) billion in England, £1.0 (0.8 to 1.2) bil-
lion in Wales, £1.6 (1.3 to 1.9) billion in Scotland
and £0.5 (0.4 to 0.6) billion in Northern Ireland.
Applying the alternative 2010 global burden of dis-
ease disability weights – for comparison with newly
published cost of illness studies that adopt these
weights – would result in a substantially lower estimate
of 81,033 (66,100 to 96,900) DALYs from sight loss and
blindness, with the value of the loss of wellbeing esti-
mated to be £7.2 (5.9 to 8.6) billion in the UK in 2013.
Fig. 1 Burden of disease across conditions in the UK, by severity of sight loss, 2013.
Note: % refers to the total burden of disease caused by the condition. Burden of disease has been determined using 2004 disability weights.
Abbreviations: AMD, age-related macular degeneration; DALYs, disability-adjusted life years
Table 2 Summary of indirect costs 2013 (£ million)
England Wales Scotland Northern Ireland UK
Lower employment 2078.5 88.0 210.9 50.0 2427.4
(1696.5–2484.2) (71.8–105.2) (172.2–252.1) (40.8–59.8) (1981.2–2901.3)
Absenteeism 65.6 3.7 6.5 1.9 77.6
(53.5–78.4) (3.0–4.4) (5.3–7.8) (1.6–2.3) (63.4–92.8)
Premature mortality 1.77 0.09 0.23 0.05 2.14
(1.44–2.11) (0.08–0.11) (0.19–0.27) (0.04–0.07) (1.75–2.56)
Informal care costs 1951.9 134.8 194.8 76.7 2358.2
(1951.9–1951.9) (134.8–134.8) (194.8–194.8) (76.7–76.7) (2358.2–2358.2)
Devices and modifications 343.8 21.5 34.1 10.2 409.6
(280.6–411) (17.6–25.7) (27.8–40.8) (8.3–12.2) (334.3–489.6)
Deadweight loss 311.8 19.8 37.0 10.3 379.0
(311.4–312.2) (19.8–19.8) (37–37.1) (10.3–10.3) (378.5–379.4)
Total 4753.3 267.8 483.6 149.2 5653.9
(4295.4–5239.8) (247.0–290.0) (437.3–532.8) (137.7–161.3) (5117.4–6223.9)
Pezzullo et al. BMC Health Services Research  (2018) 18:63 Page 7 of 13
Discussion
The results of the study indicate that sight loss and
blindness in the adult population places a large eco-
nomic cost on the UK, estimated to total £28.1 (24.0 to
32.5) billion in 2013 using 2004 disability weights, or
£15.8 (13.5 to 18.3) billion using 2010 disability weights.
The former estimate provides useful comparison with
2008 estimates and work undertaken in Canada and
Japan, which use similar disability weights. The per
capita cost of sight loss and blindness was estimated to
be £14,549, which is lower than both Canada and Japan
which were £26,587 and £28,672 respectively when con-
verted using purchasing power parity in 2007 [7, 8].
Comparing 2008 and 2013, the cost of sight loss and
blindness in the UK is estimated to have increased by
27.8%. The increase is driven by higher prevalence as
well as an estimated 39% increase in health system ex-
penditures, including a more than doubling of prescrib-
ing expenditures due to the inclusion of the cost of
ranibizumab (Lucentis) and over a 50% increase in non-
admitted expenditures. However, residential and com-
munity care costs associated with sight loss and blind-
ness have fallen over the period as the rate of accessing
these services for people with sight loss or blindness has
fallen relative to 2008. People with sight loss and blind-
ness have been disproportionately affected, with the rate
of accessing services declining by more than for other
disability groups [78]. This may be both a result of a de-
cline in the number of people with sight loss or blind-
ness that have a Certificate of Vision Impairment and a
result of cuts to social care budgets in the UK from
2010 onwards. Recently, more funding has been com-
mitted to increasing social care services and other
forms of assistance. For example, the Care Act in
England which came into effect in April 2015 legis-
lates that Local Authorities must provide minor aids
and adaptations up to the value of £1000 for the pur-
pose of assisting with nursing at home or aiding daily
living, which would have implications for expenditure
in the future.
The estimated 49% rise in productivity losses was due
to a fall in the employment rate for people with sight
loss and blindness, thereby widening the employment
gap compared to the general population. This also dir-
ectly contributed to the fall in the cost associated with
absenteeism which is dependent on the number of
employed people with sight loss and blindness.
With population ageing, the prevalence of AMD is es-
timated to have risen nearly 49% over the period 2008 to
2013. The ageing population and increasing prevalence
of diabetes in UK is associated with estimated prevalence
increases of over 40% for cataract, glaucoma and diabetic
retinopathy. However, the prevalence of sight loss and
blindness due to under-corrected refractive error has
decreased over the same period, possibly due to more
people accessing corrective services as the value of
vouchers for accessing corrective glasses and the number
of eye tests has increased.
Importantly, the burden of disease from sight loss and
blindness is estimated to have increased by more than
25% compared with 2008, indicating that the substantial
burden of disease from sight loss and blindness is still
growing in the UK.
While unavoidable, age-related conditions contribute
greatly towards the growing economic costs and bur-
den of sight loss and blindness in the UK; although, a
substantial proportion of this is still preventable. For
example, it has been estimated that the majority of vis-
ual impairment worldwide, including blindness, may be
preventable using cost-effective treatment methods
that are already available. Further, WHO Member
States (including the UK) have committed to reducing
the prevalence of avoidable visual impairment by 25%
by 2019 compared to the baseline established by the
WHO in 2010 [3].
To align with data sources, the definitions of sight
loss and blindness in this research differ slightly from
the guidelines for certifiable severely sight impaired
(blindness) and sight impaired (partial sight), which
are [79]:
 severely sight impaired is defined as BCVA of
< 3/60, or those > 3/60 and < 6/60, and < 6/60 with
the presence of contracted field of vision; and
 sight impaired is defined as BCVA of > 3/60 and
< 6/60 with full field, or > 6/60 and < 6/24 with
moderate contraction of the field, or < 6/18 or even
better with marked contraction of visual field.
This means that the prevalence numbers reported here
will not align with certifiable sight loss and blindness.
While the scope of the exercise was not to report on cer-
tifiable sight loss and blindness, it is important to recog-
nise that the economic costs and burden of sight loss
and blindness reported in this article are larger than for
certifiable sight loss and blindness alone. This distinction
is important for policy implications.
There are some limitations to this study. The
methods for this study outlined the use of grey litera-
ture and a non-systematic search strategy, noting that
this was fit-for-purpose. The estimates presented in
this article should be interpreted with this in mind.
Judgement and experience undertaking cost of illness
studies – particularly for sight loss and blindness in
the UK [4] and internationally [2, 7, 8, 80] – has
been used to ensure that the estimates are as accurate
and complete as possible without undermining the
quality of the estimates presented.
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With reference to health expenditure costs, using a
top-down approach to estimate expenditure has advan-
tages of readily available data, simplicity and low cost
to conduct analysis. However, top-down approaches
rely on accuracy of data recording. For example, when
determining direct health system expenditure in hospi-
tals, the top-down approach utilises healthcare resource
groups where expenditure is associated with eye condi-
tions as the primary cause. In contrast, a bottom-up ap-
proach that uses anonymised patient records linked to
hospital episode statistics can track expenditure for in-
dividuals identified as having sight loss or blindness re-
gardless of the primary reason for admission, such as
falls. However, linked data is often not readily available
for research purposes, and this type of approach often
requires costly data analysis. Further, a bottom-up ap-
proach can still be subject to data recording issues, in-
cluding in clinical coding data. When considering
primary diagnosis data, clinical coding errors occur in
approximately 11% of cases, and is higher for secondary
diagnosis data [81]. This can lead to poor tracking of
expenditure attributed to eye health conditions, and
limits the application of a bottom up approach. Noting
the limitations of a top down approach, the costs pre-
sented in this analysis are estimates, although the
methods which they are based on are peer-reviewed
[80], and have been utilised in other countries previ-
ously [2, 7, 8, 80].
In addition, recent healthcare or policy changes may
not be captured appropriately. For example, it was as-
sumed that there have been little to no changes in the
private expenditure for sight loss or blindness proce-
dures since 1998 [47]. The estimated private expenditure
for procedures was approximately £150 million. If there
has been a trend for these procedures to be publically
funded as with overall health expenditure [46], there
would likely be small downward correction to the total
cost of sight loss or blindness in the UK.
To estimate the R&D expenditure attributable to sight
loss and blindness, it was assumed that the proportion
of health burden due to sight loss or blindness relative
to total eye and ear health burden applied to R&D ex-
penditure. In reality, this assumption may be overly sim-
plistic for R&D expenditure, but it does provide a useful
starting point. The R&D expenditure was estimated to
be £17.0 million, which may or may not fully capture the
actual research resources devoted to sight loss and
blindness in the UK.
For community and social support services provided
to people with sight loss or blindness, unit costs were as-
sumed to be the same as for all service recipients. Also,
capital and administration expenditure was assumed to
be attributed to sight loss and blindness in a similar
proportion to overall health expenditure. These are
necessary simplifying assumptions due to a lack of avail-
able data. For example, it is still important to include the
cost of having surgery equipment and infrastructure to
provide cataract surgery. Likewise, a person with sight
loss or blindness would likely receive an average level of
support from community and social support services.
Another potential limitation is using a human capital
approach to estimate productivity losses, which can lead
to higher estimates of the cost of unemployment due to
sight loss and blindness than alternative approaches such
as the friction cost approach [9, 53]. The human capital
approach differs to the friction cost approach in that the
productivity loss of the worker’s contribution relative to
the absence of the condition is included for the duration
of the condition, whereas the friction cost approach only
includes productivity losses until the worker is replaced
[9, 53]. The human capital approach is appropriate for
industrialised countries in which there is near full em-
ployment as the removal of labour constrains economic
growth in the long run production possibilities frontier,
ceteris paribus [53, 80]. If the friction cost approach was
used, the estimated productivity loss of £2.43 billion
would be expected to be considerably smaller.
To estimate the costs of informal care provision,
average wages were used. This may be seen to over-
state the cost of informal care associated with sight
loss and blindness. However, it is important that in-
formal care is valued at average wage rates as this
captures the value of lost opportunity of undertaking
leisure time, which is proxied using the average age
and gender specific wage rate [82, 83]. Moreover, if
informal care was not provided, it is likely that formal
care would be used as a substitute where available,
which would have a higher replacement cost than the
estimates presented in this study.
Regarding absenteeism estimates, the estimated days
off work and methods are consistent with the methods
used by Roberts et al. (2010) [8] and Cruess et al. (2011)
[7], which provides useful comparison of the work im-
pacts of sight loss and blindness between Canada, Japan,
the United States and the UK. However, while the
methods are consistent, the estimates in all studies are
now based on older employment information from the
United States, and no estimates specific to the UK are
available. Furthermore, no recent studies have been
identified that attempt to classify absenteeism impacts
[6]. Further research surrounding the effect of sight loss
and blindness on work should be undertaken.
To estimate ethnicity groups by age and gender to
2050, this research utilised Greater London Authority
projections [25]. A number of other methodologies and
sources have attempted to provide ethnicity projections
over the long term. Prominent projections for the UK
suggest that the ethnic minority share of the population
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would increase from approximately 13% in 2001 to be-
tween 20 and 25% [84] to 44% [85] by 2051 and 2056,
respectively. This contrasts with minority groups repre-
senting approximately 18% of the total UK population
by 2050 estimated in this research. A decision was made
to use Greater London Authority projections as data was
available by year and did not require linear interpolation
between 2001 and 2051. It is noted that there is substan-
tial uncertainty surrounding population and ethnicity
group projections. Although ethnic composition does
not affect prevalence substantially, sensitivity analysis
was nonetheless conducted on prevalence estimates to
account for this uncertainty. Confidence intervals from
prevalence studies were weighted by sample size to esti-
mate a robust prevalence range. The ranges presented in
this research reflect a decrease or increase in prevalence
by 18.4% and 19.5%, respectively.
Finally, quality adjusted life years (QALYs) are typically
used in the UK for cost effectiveness analysis [5, 86].
This means that DALYs are unfamiliar to the UK con-
text. DALYs are recommended in the Vancouver group
guidelines to measure the burden of disease due to sight
loss and blindness, measuring the disability imposed on
an individual or the loss of healthy life years [80]. DALYs
have been used in a number of studies to estimate the
cost burden of sight loss and blindness internationally,
and provide a useful basis for comparison across coun-
tries. [2, 82, 87] QALYs often rely on preference-based
health related quality of life measures elicited from gen-
eral population samples or from groups of people with
the specific condition (e.g. sight loss or blindness),
which can make it difficult to make comparisons
internationally or with other conditions [88]. DALYs
also use a standard life expectancy tables across coun-
tries, which make international comparisons easier
[88]. For these reasons, DALYs are appropriate and
useful in cost of illness studies.
Going forward, more precise and reliable epidemio-
logical information is required to make better estimates
of the total national prevalence and costs associated with
sight loss and blindness. As the majority of prevalence
studies are almost a decade old, the prevalence estimates
may not capture those in non-community settings,
people with learning disabilities and dementia, or recent
advances in treatment. In particular, the effects of recent
growth in the use of anti-VEGF therapies to treat AMD
and diabetic retinopathy are unlikely to be taken into ac-
count in prevalence estimates, although they were in the
cost estimates. Anti-VEGF medicines have been shown
to both slow and reverse some instances of sight loss
and blindness [89].
Changes in eligibility for sight tests funded by the Na-
tional Health Service (NHS) may have altered detection
rates, which may then have resulted in earlier treatment
and a reduction in the prevalence of sight loss and blind-
ness. Specifically, in 2006, NHS Scotland expanded the
eligibility criteria for NHS funded eye tests so that the
entire Scottish population receives free eye tests. Subse-
quent adjustments to eligibility in relation to the fre-
quency of free eyes tests were also made. Increased
eligibility for comprehensive eye examinations may have
benefits from the societal perspective in Scotland if pol-
icy encourages a shift in emphasis from the sale of op-
tical appliances to eye health, and if this leads to higher
risk individuals receiving eye examinations [90].
These limitations of prevalence data highlight the need
for high quality, population-based epidemiological stud-
ies to track the prevalence of all eye conditions in the
UK and the impacts of treatment over time. Building on
the evidence base longitudinally in this manner could
also capture changes that are occurring within the
population (e.g. in risk factors such as smoking rates),
enabling more accurate and timely estimates of the
economic costs associated with sight loss and blind-
ness. UK-wide population projections that include
ethnicity splits would also be highly beneficial for fu-
ture studies estimating the economic impact of sight
loss and blindness in the UK.
Despite the limitations with recent prevalence data,
this study provides an important, and likely accurate pic-
ture of the economic costs associated with sight loss and
blindness in the UK. To provide some reassurance to
the reader that this limitation in prevalence data does
not undermine the overall estimates presented in this
study, we examined the number of people who are regis-
tered as partially sighted or blind (i.e. certifiable sight
loss or blindness) with England councils. In 2008,
309,265 people were registered as either partially sighted
or blind in England [91]. In 2014, 291,100 people were
registered as either partially sighted or blind, a decrease
of 6% [91]. The number of people registering with coun-
cils may have declined due to changes in care needs,
various policy considerations or an overall decrease in
prevalence. However, the magnitude of this change indi-
cates that the expected prevalence in 2013 is within the
sensitivity analysis conducted, noting that this is on the
lower end of the sensitivity analysis at worst.
Overall, the large prevalence of sight loss and blindness
means sight loss in the UK adult population imposes a
substantial cost on public funds, private expenditure, and
health. This study did not estimate the expected large, and
additional costs, associated with sight loss and blindness
for children (less than 18 years of age) so the total cost is
expected to be underestimated.
Data on the prevalence of childhood sight loss and blind-
ness in the UK is limited and variable. More research needs
to be undertaken into measuring childhood sight loss and
blindness and the associated economic costs within the UK.
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Conclusion
Estimating the cost of sight loss and blindness is essen-
tial if their socioeconomic impact is to be fully under-
stood. The large prevalence of sight loss and blindness
in the UK population imposes significant costs on public
funds, private expenditure, and health – estimated to
total £28.1 (24.0 to 32.5) billion in 2013 using 2004 dis-
ability weights, or £15.8 (13.5 to 18.3) billion using 2010
disability weights. Prevalence estimates relied on dated
epidemiological studies and may not capture recent ad-
vances in treatment, or the substantial increase in the
prevalence of age-related sight-impairing conditions due
to demographic ageing, and associated increases in their
costs. Importantly, this study takes account of new data
to update the understanding of the economic impact of
sight loss and blindness in the UK, enabling inter-
national comparison and an estimate of the change over
the five years between 2008 and 2013. Finally, this study
highlights the need for population-based studies that
track the prevalence of sight-impairing eye conditions
and treatment effects over time.
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